Preparation method of pharmaceutical composition for treating type II diabetes

Abstract

The invention relates to a preparation method of a pharmaceutical composition for treating type II diabetes, belonging to the medical preparations containing organic ingredients, particularly relating to a preparation method of a pharmaceutical composition of metformin hydrochloride and glimepiride. In the preparation method, the metformin hydrochloride and the glimepiride are taken as active ingredients of the pharmaceutical composition, the metformin hydrochloride is firstly prepared into pill cores by adopting an osmotic pump technology and then the metformin hydrochloride pill cores are coated with the glimepiride by using a coating technology. The preparation method comprises the following steps: 1), preparing the metformin hydrochloride and pharmaceutically acceptable auxiliary materials into pills which are coated with semipermeable membrane layers, punching by laser and producing the pill cores; and 2), preparing the glimepiride and the pharmaceutically acceptable auxiliary materials into a coating liquid dissolved in stomach and carrying out coating on the pill cores in step 1. The invention provides the preparation method of the pharmaceutical composition for treating the type II diabetes, wherein the pharmaceutical composition steady and slowly releases drugs, has reduced administration times, good patients compliance, small side effect and small tablet volume, is less influenced by pH values of different segments of a gastrointestinal tract, and is convenient for administration for the patients.

Description

technical field [0001] The invention is a preparation method of a pharmaceutical composition for treating type 2 diabetes. It belongs to pharmaceutical preparations containing organic ingredients. In particular, it relates to a preparation method of the pharmaceutical composition of metformin hydrochloride and glimepiride. Background technique [0002] Metformin hydrochloride is a biguanide antidiabetic drug, which mainly acts on extrapancreatic islet tissues, inhibits intestinal absorption of glucose, increases the utilization of glucose by peripheral tissues, reduces hepatic glycogenogenesis, thereby achieving the effect of lowering blood sugar, and at the same time, it has the effect of reducing insulin resistance. effect. It is mainly used clinically for obese diabetic patients. [0003] Andrx Company of the United States developed metformin hydrochloride osmotic pump tablets using SCOT (single-composition osmotic technology) technology, and it was launched in the Uni...

AI Technical Summary

Problems solved by technology

[0016] 1. The drug release of metformin hydrochloride in the sustained-release preparation is not stable enough, and the blood drug concentration in the body still fluctuates greatly;

[0017] 2. Since metformin hydrochloride is very water-soluble, in order to control drug release, more sustained-release materials are needed, and the amount of excipients is large, resulting in large tablet volume and poor patient compliance;

[0018] 3. Although the side effects of sustained-release preparations are smaller than those of ordinary tablets, the incidence of hypoglycemia and gastrointestinal discomfort is still high;

Images